(Q33660573)

28 July 2017

title

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (English)

1 reference

estrogen-receptor positive breast cancer

28 July 2017

main subject

0 references

1 reference

Martín A Rivas

4

0 references

Mitch Dowsett

Mitch Dowsett

16

0 references

Sunil Pancholi

Sunil Pancholi

14

0 references

Violeta Serra

Violeta Serra

19

0 references

Javier Cortes

Javier Cortés

12

0 references

Richard Elliott

13

Richard Elliott

1 reference

28 July 2017

author name string

Maria Teresa Herrera-Abreu

1

1 reference

28 July 2017

Marta Palafox

2

1 reference

28 July 2017

Uzma Asghar

3

1 reference

28 July 2017

Rosalind J Cutts

5

1 reference

28 July 2017

Isaac Garcia-Murillas

6

1 reference

28 July 2017

Alex Pearson

7

1 reference

28 July 2017

Marta Guzman

8

1 reference

28 July 2017

Olga Rodriguez

9

1 reference

28 July 2017

Judit Grueso

10

1 reference

28 July 2017

Meritxell Bellet

11

1 reference

28 July 2017

José Baselga

15

1 reference

28 July 2017

Lesley-Ann Martin

17

1 reference

28 July 2017

Nicholas C Turner

18

1 reference

28 July 2017

language of work or name

English

0 references

publication date

28 March 2016

1 reference

28 July 2017

1 reference

28 July 2017

volume

76

1 reference

28 July 2017

issue

8

1 reference

28 July 2017

page(s)

2301-2313

1 reference

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

The history and future of targeting cyclin-dependent kinases in cancer therapy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

An update on the medical management of breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Cyclin D activates the Rb tumor suppressor by mono-phosphorylation

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Noninvasive detection of HER2 amplification with plasma DNA digital PCR.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Comprehensive molecular portraits of human breast tumours

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Cyclin D as a therapeutic target in cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Cell cycle, CDKs and cancer: a changing paradigm

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Cellular mechanisms of tumour suppression by the retinoblastoma gene.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Specific protection against breast cancers by cyclin D1 ablation

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Molecular portraits of human breast tumours

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5426059

Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27020857

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/0008-5472.CAN-15-0728

1 reference

28 July 2017

1 reference

28 July 2017

1 reference